Trial
NCT01338857
Sorafenib in Children and Young Adults With Recurrent or Progressive Low-Grade Astrocytomas
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
NYU Langone Health
Collaborators
Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma
Condition
neurofibromatosis1 (NF1)
Intervention
Sorafenib (Nexavar)
Why stopped
Sorafenib ineffective for tx of recurrent or progressive PLGA
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-02-17